Search
difelikefalin (Korsuva)
Indications:
- treatment of moderate-severe pruritus in adults undergoing hemodialysis
Dosage:
- 0.5. ug/kg IV bolus injection at the end of hemodialysis
- administer within 60 minutes of syringe preparation
Injection: 50 ug/mL
Adverse effects:
- diarrhea, dizziness, nausea, gait disturbances, falls, hyperkalemia, headache, somnolence, mental status change
Mechanism of action:
- kappa opioid receptor agonist
Interactions
drug adverse effects of opiates
General
opioid receptor agonist (narcotic)
References
- Weiner DE, Vervloet MG, Walpen S, et al; trial investigators.
Safety and effectiveness of difelikefalin in patients with moderate-to-severe
pruritus undergoing hemodialysis: an open-label, multicenter study.
Kidney Med. 2022;4:100542.
PMID: 36185706
- difelikefalin (Rx) Korsuva
https://reference.medscape.com/drug/korsuva-difelikefalin-4000195